INOMAX (Nitric Oxide) Patent Expiration, LOE Window & CMS Spending

INOMAX (Nitric Oxide) by Mallinckrodt: FDA Orange Book core substance LOE 2035-08-19 (last listed 2036-11-03), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMallinckrodt
FDA Application & PathwayN020845 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-08-19
Last Listed Patent or Exclusivity Date2036-11-03
Orange Book Patents (*PED Extensions)53 patents (26 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mallinckrodt across sibling Meru public-data platforms.